Nonoperating Income (Expense) in USD of Inhibrx, Inc. from Q3 2019 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Inhibrx, Inc. quarterly/annual Nonoperating Income (Expense) history and change rate from Q3 2019 to Q1 2024.
  • Inhibrx, Inc. Nonoperating Income (Expense) for the quarter ending 31 Mar 2024 was -$4.89M, a 5.15% increase year-over-year.
  • Inhibrx, Inc. Nonoperating Income (Expense) for the twelve months ending 31 Mar 2024 was -$20.2M, a 6.41% decline year-over-year.
  • Inhibrx, Inc. annual Nonoperating Income (Expense) for 2023 was -$20.5M, a 27.3% decline from 2022.
  • Inhibrx, Inc. annual Nonoperating Income (Expense) for 2022 was -$16.1M, a 210% decline from 2021.
  • Inhibrx, Inc. annual Nonoperating Income (Expense) for 2021 was -$5.2M, a 36.5% increase from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Change (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Change (%)

Inhibrx, Inc. Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$20.2M -$4.89M +$265K +5.15% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2024
Q4 2023 -$20.5M -$3.69M +$1.73M +32% 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2024
Q3 2023 -$22.2M -$5.96M -$638K -12% 01 Jul 2023 30 Sep 2023 10-Q 09 Nov 2023
Q2 2023 -$21.6M -$5.71M -$2.58M -82.3% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2023
Q1 2023 -$19M -$5.15M -$2.91M -130% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024
Q4 2022 -$16.1M -$5.42M -$3.63M -203% 01 Oct 2022 31 Dec 2022 10-K 28 Feb 2024
Q3 2022 -$12.5M -$5.32M -$3.54M -199% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 -$8.93M -$3.13M -$2.22M -244% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023
Q1 2022 -$6.71M -$2.24M -$1.51M -207% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023
Q4 2021 -$5.2M -$1.79M -$1.25M -231% 01 Oct 2021 31 Dec 2021 10-K 06 Mar 2023
Q3 2021 -$3.96M -$1.78M +$2.67M +60% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022
Q2 2021 -$6.63M -$909K -$191K -26.6% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022
Q1 2021 -$6.44M -$729K +$1.75M +70.6% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022
Q4 2020 -$8.19M -$539K 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2022
Q3 2020 -$4.45M +$1.76M +28.4% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021
Q2 2020 -$718K 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021
Q1 2020 -$2.48M 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021
Q3 2019 -$6.22M 01 Jul 2019 30 Sep 2019 10-Q 13 Nov 2020

Inhibrx, Inc. Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$20.5M -$4.4M -27.3% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2024
2022 -$16.1M -$10.9M -210% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2024
2021 -$5.2M +$2.99M +36.5% 01 Jan 2021 31 Dec 2021 10-K 06 Mar 2023
2020 -$8.19M -$1.4M -20.7% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2022
2019 -$6.79M 01 Jan 2019 31 Dec 2019 10-K 12 Mar 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.